Literature DB >> 15548448

Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.

A Haferkamp1, B Schurch, A Reitz, U Krengel, J Grosse, G Kramer, S Schumacher, P J Bastian, R Büttner, S C Müller, M Stöhrer.   

Abstract

INTRODUCTION: Endoscopical injections of Botulinum toxin type A into the detrusor muscle are gaining clinical acceptance in the treatment of neurogenic detrusor overactivity. Structural effects of Botulinum toxin type A are only known from studies on striated muscles, where a widespread nerve sprouting occurs temporarily. The aim of this study was to evaluate the ultrastructural effects of Botulinum toxin type A injections on the human detrusor.
MATERIAL AND METHODS: 30 detrusor biopsies were obtained from 24 patients with neurogenic detrusor overactivity. Patients were divided into two groups: Group I included 13 biopsies from patients before the first Botulinum toxin type A injection. Group II included 6 biopsies from patients within 3 months after the first injection and 11 biopsies at the time of decreasing efficacy of Botulinum toxin type A. The biopsies were processed by standard procedure for detailed electron microscopic study and evaluated by 2 examiners without prior knowledge of clinical/urodynamic data.
RESULTS: No statistically significant detrusor changes have been found concerning muscle cell fascicle structure (p = 0.445), width of intercellular space (p = 0.482) and number/kind of muscle cell junctions (p = 0.443). A median of 70% of intrinsic axon terminals presented with signs of degeneration in group I, a median of 66% in group II (p = 0.840). Out of 309 evaluated axon terminals in both groups, 1 sprouting axon was found in group I, 3 sprouting axons in group II (p = 0.864). Specimen from group I and group II showed only limited collagen deposits within the detrusor. No changes in the ultrastructure of the detrusor have been observed in those biopsies obtained before and after the Botulinum toxin type A injection of the same patient.
CONCLUSION: This study verifies our earlier report of severe intrinsic axon degeneration in the detrusor of patients with neurogenic detrusor overactivity. It also shows nearly no structural differences of the detrusor before and after Botulinum toxin type A injections. Contrary to reports of striated muscle, axonal sprouting within the detrusor was very limited after Botulinum toxin type A injections indicating pathophysiologically different reactions to the toxin either between striated muscle and smooth muscle or between different treated diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548448     DOI: 10.1016/j.eururo.2004.07.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  35 in total

Review 1.  Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Authors:  Catherine A Thomas; Yao-Chi Chuang; Antonella Giannantoni; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 2.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

3.  [Intravesical therapy for overactive bladder].

Authors:  J Pannek; U Grigoleit; R Wormland; M Goepel
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

4.  [How come? What for? Why? Questions on the topic of "Botulinum toxin in urology"].

Authors:  H Schulte-Baukloh; H H Knispel
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

5.  [Seven years of botulinum toxin type A in the treatment of neurogenic detrusor hyperactivity].

Authors:  M Stöhrer; A Wolff; G Kramer; R Steiner; D Löchner-Ernst; D Leuth; U Steude; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 6.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

Review 7.  Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.

Authors:  Nachiketh Soodana Prakash; Diana M Lopategui; Christopher Gomez
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

8.  Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases.

Authors:  Christopher Goodrich; Henry York; Andrew Shapiro; Peter Howard Gorman
Journal:  J Spinal Cord Med       Date:  2019-01-31       Impact factor: 1.985

9.  Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.

Authors:  Ibrahim Fathi Ghalayini; Mohammed A Al-Ghazo; Ziad Ali Elnasser
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

10.  Intrapouch injections of botulinum toxin type A for the management of unit contractions of a continent urinary diversion.

Authors:  Arash Gharajeh; Stephen S Steele; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2008-08       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.